Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Jérôme, Desramé"'
Autor:
Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, François Ghiringhelli, Éric François, Julien Taieb, Denis Smith, Christelle de la Fouchardière, Jérôme Desramé, Emmanuelle Samalin, Aurélie Parzy, Nabil Baba-Hamed, Olivier Bouché, David Tougeron, Laëtitia Dahan, Farid El Hajbi, Marion Jacquin, Magali Rebucci-Peixoto, Laurie Spehner, Véronique Vendrely, Dewi Vernerey, Christophe Borg
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating i
Externí odkaz:
https://doaj.org/article/07cff244a8334a279f68769e303b762a
Autor:
Emilie Charton, Jean‐Baptiste Bachet, Pascal Hammel, Jérôme Desramé, Benoist Chibaudel, Romain Cohen, Philippe Debourdeau, Jérome Dauba, Thierry Lecomte, Jean‐François Seitz, Christophe Tournigand, Thomas Aparicio, Véronique Guerin‐Meyer, Julien Taieb, Julien Volet, Christophe Louvet, Amélie Anota, Franck Bonnetain
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5079-5088 (2019)
Abstract Background The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients w
Externí odkaz:
https://doaj.org/article/ea9e9d8aac3c4e91a964a297380cb6f7
Autor:
Camille Evrard, Thomas Aparicio, Emilie Soularue, Karine Le Malicot, Jérôme Desramé, Damien Botsen, Farid El Hajbi, Daniel Gonzalez, Come Lepage, Olivier Bouché, David Tougeron, on behalf of the DURIGAST—PRODIGE 59 Investigators/Collaborators
Publikováno v:
Biomedicines, Vol 10, Iss 5, p 1211 (2022)
Efficacy of immune checkpoint inhibitors (ICI) as monotherapy in 2nd line treatment for gastric or gastro-oesophageal junction (GEJ) adenocarcinoma is low, with no evaluation of efficacy and safety of ICI combined with chemotherapy. The DURIGAST PROD
Externí odkaz:
https://doaj.org/article/e5f33636db76484d82559bf48a274df7
Autor:
Sylvain Manfredi, Eric Terrebonne, David Malka, Prodige Investigators, Emilie Barbier, Valérie Lebrun Ly, Hervé Perrier, Laetitia Dahan, François Ghiringhelli, Faiza Khemissa Akouz, Emilie Soularue, Thierry Lecomte, Cindy Neuzillet, Jean-Marc Phelip, Yann Molin, Vincent Bourgeois, Samy Louafi, Julien Edeline, Romain Coriat, Jérôme Desramé, Pierre Michel
Publikováno v:
Journal of Clinical Oncology. 40:262-271
PURPOSE Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. METHODS In this open-label, randomized phase II-III study, patients with locally advanced or metastatic BTC and an Eastern Coo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffc6922596ffa4f04c494f30c751c238
https://doi.org/10.1200/jco.21.00679
https://doi.org/10.1200/jco.21.00679
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd88624f7c463a97631291b4cd6de31a
https://doi.org/10.1200/jco.20.03329
https://doi.org/10.1200/jco.20.03329
Autor:
Laetitia Dahan, Emilie Barbier, David Tougeron, Jean Philippe Metges, Samy Louafi, Christophe Borg, Roger Faroux, Lila Gaba, Christophe Louvet, Jérôme Desramé, Astrid Lièvre, Violaine Randrian, Frédéric Di Fiore, Sylvain Manfredi, Antoine Adenis, Gilles Breysacher, Pierre Laurent-Puig, Laurent Mineur, Guillaume Roquin, Anthony Lopez
Publikováno v:
Digestive and Liver Disease
Digestive and Liver Disease, 2020, 52 (3), pp.347-350. ⟨10.1016/j.dld.2019.11.014⟩
Digestive and Liver Disease, WB Saunders, 2020, 52 (3), pp.347-350. ⟨10.1016/j.dld.2019.11.014⟩
Digestive and Liver Disease, 2020, 52 (3), pp.347-350. ⟨10.1016/j.dld.2019.11.014⟩
Digestive and Liver Disease, WB Saunders, 2020, 52 (3), pp.347-350. ⟨10.1016/j.dld.2019.11.014⟩
Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::593a0c50d21de5ed2f55f21df3647dfc
https://doi.org/10.1016/j.dld.2019.11.014
https://doi.org/10.1016/j.dld.2019.11.014
Autor:
Pierre Laurent-Puig, May Mabro, Valérie Taly, Jaafar Bennouna, Claire Mulot, Julie Henriques, Olivier Bouché, Jérôme Desramé, Joëlle Egreteau, Thibault Mazard, C. Lepere, Laurent Mineur, Christophe Louvet, Dewi Vernerey, Camille Bourreau, Kariman Chaba, Aimery de Gramont, Katia Hormigos, Julien Taieb, Thierry André
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (20), pp.5638-5646. ⟨10.1158/1078-0432.CCR-21-0271⟩
Clinical Cancer Research, 2021, 27 (20), pp.5638-5646. ⟨10.1158/1078-0432.CCR-21-0271⟩
Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (20), pp.5638-5646. ⟨10.1158/1078-0432.CCR-21-0271⟩
Clinical Cancer Research, 2021, 27 (20), pp.5638-5646. ⟨10.1158/1078-0432.CCR-21-0271⟩
Purpose:Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in the phase III IDEA-France trial.Experimental Design:ctDNA was tested for WIF1 and NP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4a9b93e3b0e51094fa759c8dfcfe35e
https://www.hal.inserm.fr/inserm-03405591
https://www.hal.inserm.fr/inserm-03405591
Autor:
Cindy Serdjebi, Johan Gagnière, Jérôme Desramé, Francine Fein, Rosine Guimbaud, Eric François, Thierry André, Jean-François Seitz, Carole Montérymard, Dominique Arsene, Julien Volet, Abakar Abakar-Mahamat, Thierry Lecomte, Véronique Guerin-Meyer, Jean-Louis Legoux, Gaël Deplanque, Pierre Guillet, Joseph Ciccolini, Côme Lepage, Laetitia Dahan
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135907 (2015)
Because cytidine deaminase (CDA) is the key enzyme in gemcitabine metabolism, numerous studies have attempted to investigate impact of CDA status (i.e. genotype or phenotype) on clinical outcome. To date, data are still controversial because none of
Externí odkaz:
https://doaj.org/article/55333137924b4b87813ce2431fa811d4
Autor:
Sabrina Pierre, Côme Lepage, Thierry Lecomte, Frédéric Bibeau, Karine Le Malicot, Aziz Zaanan, Stefano Kim, Astrid Lièvre, Thomas Aparicio, David Tougeron, Olivier Bouché, Harry Sokol, Pierre Laurent-Puig, Daniel Gonzalez, Farid El Hajbi, Frédéric Di Fiore, Christophe Louvet, Jérôme Desramé, Rosine Guimbaud, Camille Evrard, Benoist Chibaudel
Publikováno v:
Digestive and Liver Disease
Digestive and Liver Disease, WB Saunders, 2021, 53 (4), pp.420-426. ⟨10.1016/j.dld.2020.11.036⟩
Digestive and Liver Disease, 2021, 53 (4), pp.420-426. ⟨10.1016/j.dld.2020.11.036⟩
Digestive and Liver Disease, WB Saunders, 2021, 53 (4), pp.420-426. ⟨10.1016/j.dld.2020.11.036⟩
Digestive and Liver Disease, 2021, 53 (4), pp.420-426. ⟨10.1016/j.dld.2020.11.036⟩
International audience; Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e610d55cb2ec70bff1e1c3f951c0b829
https://hal.archives-ouvertes.fr/hal-03102304/document
https://hal.archives-ouvertes.fr/hal-03102304/document
Autor:
Jérôme Desramé, Florence Mary, Simon Pernot, Thomas Aparicio, Laetitia Dahan, Lysianne Marthey, François-Xavier Caroli-Bosc, Alexandra Lapeyre-Prost, Julien Taieb, Côme Lepage, Thierry Lecomte, Karine Le Malicot, Julie Sigrand, Solene Doat
Publikováno v:
Clinical Colorectal Cancer
Clinical Colorectal Cancer, Elsevier, 2020, 19 (4), pp.285-290. ⟨10.1016/j.clcc.2020.06.003⟩
Clinical Colorectal Cancer, 2020, 19 (4), pp.285-290. ⟨10.1016/j.clcc.2020.06.003⟩
Clinical Colorectal Cancer, Elsevier, 2020, 19 (4), pp.285-290. ⟨10.1016/j.clcc.2020.06.003⟩
Clinical Colorectal Cancer, 2020, 19 (4), pp.285-290. ⟨10.1016/j.clcc.2020.06.003⟩
Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). Our aim was to investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3cadda315cf4cb394e1fec82bbbc51e
https://hal.univ-angers.fr/hal-03284418
https://hal.univ-angers.fr/hal-03284418